vs
Side-by-side financial comparison of Valens Semiconductor Ltd. (VLN) and Xtant Medical Holdings, Inc. (XTNT). Click either name above to swap in a different company.
Xtant Medical Holdings, Inc. is the larger business by last-quarter revenue ($32.4M vs $17.3M, roughly 1.9× Valens Semiconductor Ltd.). Xtant Medical Holdings, Inc. runs the higher net margin — 0.2% vs -42.2%, a 42.4% gap on every dollar of revenue. On growth, Valens Semiconductor Ltd. posted the faster year-over-year revenue change (8.1% vs 2.7%). Xtant Medical Holdings, Inc. produced more free cash flow last quarter ($5.0M vs $-4.9M).
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
Xtant Medical Holdings, Inc. is a global medical technology company that develops, manufactures and markets orthobiologic products, neurosurgery devices, and regenerative medicine solutions for orthopedic and neurological care providers. It serves patients and medical institutions across North America, Europe and the Asia-Pacific, with core segments covering spinal surgery supplies and bone regeneration products.
VLN vs XTNT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.3M | $32.4M |
| Net Profit | $-7.3M | $57.0K |
| Gross Margin | 63.0% | 54.9% |
| Operating Margin | -46.4% | -2.9% |
| Net Margin | -42.2% | 0.2% |
| Revenue YoY | 8.1% | 2.7% |
| Net Profit YoY | 29.3% | 101.8% |
| EPS (diluted) | $-0.07 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $32.4M | ||
| Q3 25 | $17.3M | $33.3M | ||
| Q2 25 | $17.1M | $35.4M | ||
| Q1 25 | $16.8M | $32.9M | ||
| Q4 24 | — | $31.5M | ||
| Q3 24 | $16.0M | $27.9M | ||
| Q2 24 | $13.6M | $29.9M | ||
| Q1 24 | — | $27.9M |
| Q4 25 | — | $57.0K | ||
| Q3 25 | $-7.3M | $1.3M | ||
| Q2 25 | $-7.2M | $3.5M | ||
| Q1 25 | $-8.3M | $58.0K | ||
| Q4 24 | — | $-3.2M | ||
| Q3 24 | $-10.4M | $-5.0M | ||
| Q2 24 | $-8.9M | $-3.9M | ||
| Q1 24 | — | $-4.4M |
| Q4 25 | — | 54.9% | ||
| Q3 25 | 63.0% | 66.1% | ||
| Q2 25 | 63.5% | 68.6% | ||
| Q1 25 | 62.9% | 61.5% | ||
| Q4 24 | — | 50.9% | ||
| Q3 24 | 56.4% | 58.4% | ||
| Q2 24 | 61.4% | 62.1% | ||
| Q1 24 | — | 62.1% |
| Q4 25 | — | -2.9% | ||
| Q3 25 | -46.4% | 7.6% | ||
| Q2 25 | -43.3% | 13.1% | ||
| Q1 25 | -56.2% | 3.2% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | -76.3% | -13.5% | ||
| Q2 24 | -69.2% | -9.8% | ||
| Q1 24 | — | -12.4% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | -42.2% | 3.9% | ||
| Q2 25 | -42.1% | 10.0% | ||
| Q1 25 | -49.4% | 0.2% | ||
| Q4 24 | — | -10.0% | ||
| Q3 24 | -64.6% | -18.0% | ||
| Q2 24 | -65.2% | -12.9% | ||
| Q1 24 | — | -15.8% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | $-0.07 | $0.01 | ||
| Q2 25 | $-0.07 | $0.02 | ||
| Q1 25 | $-0.08 | $0.00 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $-0.10 | $-0.04 | ||
| Q2 24 | $-0.08 | $-0.03 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.5M | $17.1M |
| Total DebtLower is stronger | — | $11.0M |
| Stockholders' EquityBook value | $108.8M | $51.0M |
| Total Assets | $136.7M | $94.1M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $17.1M | ||
| Q3 25 | $93.5M | $10.4M | ||
| Q2 25 | $102.7M | $6.9M | ||
| Q1 25 | $112.5M | $5.0M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | $133.1M | $6.6M | ||
| Q2 24 | $105.9M | $5.4M | ||
| Q1 24 | — | $4.5M |
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $16.8M |
| Q4 25 | — | $51.0M | ||
| Q3 25 | $108.8M | $50.4M | ||
| Q2 25 | $116.5M | $48.5M | ||
| Q1 25 | $128.6M | $43.9M | ||
| Q4 24 | — | $43.0M | ||
| Q3 24 | $147.0M | $45.7M | ||
| Q2 24 | $153.5M | $45.0M | ||
| Q1 24 | — | $47.7M |
| Q4 25 | — | $94.1M | ||
| Q3 25 | $136.7M | $106.3M | ||
| Q2 25 | $144.8M | $103.5M | ||
| Q1 25 | $154.6M | $95.8M | ||
| Q4 24 | — | $93.8M | ||
| Q3 24 | $171.9M | $98.9M | ||
| Q2 24 | $175.8M | $95.6M | ||
| Q1 24 | — | $93.9M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.7M | $5.4M |
| Free Cash FlowOCF − Capex | $-4.9M | $5.0M |
| FCF MarginFCF / Revenue | -28.5% | 15.4% |
| Capex IntensityCapex / Revenue | 1.6% | 1.2% |
| Cash ConversionOCF / Net Profit | — | 94.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-11.0M | $10.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.4M | ||
| Q3 25 | $-4.7M | $4.6M | ||
| Q2 25 | $-211.0K | $1.3M | ||
| Q1 25 | $-7.6M | $1.3M | ||
| Q4 24 | — | $665.0K | ||
| Q3 24 | $3.0M | $-1.7M | ||
| Q2 24 | $-225.0K | $-5.1M | ||
| Q1 24 | — | $-5.8M |
| Q4 25 | — | $5.0M | ||
| Q3 25 | $-4.9M | $4.2M | ||
| Q2 25 | $-330.0K | $910.0K | ||
| Q1 25 | $-8.0M | $87.0K | ||
| Q4 24 | — | $-7.0K | ||
| Q3 24 | $2.2M | $-3.8M | ||
| Q2 24 | $-460.0K | $-5.7M | ||
| Q1 24 | — | $-6.5M |
| Q4 25 | — | 15.4% | ||
| Q3 25 | -28.5% | 12.6% | ||
| Q2 25 | -1.9% | 2.6% | ||
| Q1 25 | -47.3% | 0.3% | ||
| Q4 24 | — | -0.0% | ||
| Q3 24 | 14.0% | -13.7% | ||
| Q2 24 | -3.4% | -18.9% | ||
| Q1 24 | — | -23.4% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | 1.6% | 1.3% | ||
| Q2 25 | 0.7% | 1.0% | ||
| Q1 25 | 2.1% | 3.6% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | 4.5% | 7.5% | ||
| Q2 24 | 1.7% | 1.9% | ||
| Q1 24 | — | 2.8% |
| Q4 25 | — | 94.39× | ||
| Q3 25 | — | 3.53× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 22.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VLN
Segment breakdown not available.
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
